Trial Profile
A Phase 2, Multi-Center, Three-Arm, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Endometriosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Telapristone (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Sponsors Repros Therapeutics
- 25 Jul 2017 Status changed from active, no longer recruiting to completed.
- 07 Sep 2016 Based on the results from this trial the company is preparing to interact with the FDA, according to a Repros Therapeutics media release.
- 07 Sep 2016 Primary endpoint has been met. (Change in individual BBSS pain scores), according to a Repros Therapeutics media release.